-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Buy on Halozyme Therapeutics, Raises Price Target to $90

Benzinga·02/19/2026 18:38:50
Listen to the news
Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $75 to $90.